Considering most liver cancer cases are caused by viral hepatitis, 54% of liver cancer diagnoses are due to HBV infection and 31% to HCV infection1, EASL would like to see the new European Code Against Cancer provide more comprehensive information on the link between viral hepatitis and cancer.
Read More
This final update of the EASL Recommendations on Treatment of Hepatitis C series is intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process, by describing the current optimal management of patients with acute and chronic HCV infections.
Read More
Viral hepatitis is an inflammatory condition of the liver and the7th most frequent cause of death in the world, surpassing HIV
Full version of Policy Statement
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. As a result, worldwide there are approximately 71 million chronically infected individuals. Clinical care for patients with HCV-related liver disease is advancing considerably. Most importantly thanks to an enhanced understanding of the pathophysiology of the disease. And also because of developments in diagnostic procedures and improvements in therapy and prevention. EASL Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards.
Read More